Navigation Links
Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization (IVF)
Date:9/30/2009

ANN ARBOR, Mich., Sept. 30 /PRNewswire/ -- Incept BioSystems, Inc. ("Incept" or the "Company"), a privately-held biomedical device company using patented microfluidic technology developed at the University of Michigan, announced today that it has initiated the first U.S. human clinical trial of its proprietary SMART Embryo Culture System. The microscale SMART technology platform is designed to improve the in vitro manipulation, performance, and viability of embryos for the treatment of patients undergoing in vitro fertilization (IVF).

"We are delighted to be taking part in this important clinical trial," noted Dr. Thomas Pool Ph.D., H.C.L.D. of the Fertility Center of San Antonio and a trial investigator. "Infertility continues to be a major healthcare issue, with only about 30% of IVF cycles nationwide resulting in a live birth using today's procedure. Incept's SMART Embryo Culture System is an important technological advance in the industry and may therefore offer couples a much more efficient and reliable procedure for IVF."

The study will assess the SMART system's capacity to safely enhance morphological embryo development and survival rates at day three of development, in comparison to the existing practice of growing embryos in a conventional culture dish. The prospective, multi-center, randomized performance study, which will take place at three investigational sites, is expected to enroll approximately 400 to 600 embryos from up to 40 couples who have been diagnosed with infertility and are planning to undergo IVF and embryo transfer.

"We are very excited about the potential benefits of using the SMART culture system to improve IVF," said Christopher Bleck, President and Chief Executive Officer of Incept. "This is a key milestone for the Company, which we expect will lead to a second study in 2010 that will evaluate implantation and pregnancy rates using the SMART culture system."

About IVF and Incept BioSystems' SMART Embryo Culture System

IVF is a technique in which eggs are retrieved from a woman's ovary and inseminated, resulting in fertilized eggs which are then cultured in specialized laboratory conditions. It is the primary treatment for infertility today, common when other methods of achieving conception have failed. According to the Society for Reproductive Technology, in 2007, women in the U.S. underwent approximately 132,700 IVF cycles and it is estimated that there will be more than one million cycles worldwide in 2009.

Unlike the current IVF practice of culturing embryos in a static environment (i.e., a microdrop in a culture dish), Incept's microfluidic system brings embryologists a significant step closer to natural conditions by providing a continuous, refreshable culture microenvironment while using industry-standard IVF culture medium. It is believed that this dynamic environment may provide a beneficial physical stimulus to the embryos in addition to replenishing the embryos with fresh medium while removing metabolized waste products. Mouse and bovine studies conducted by researchers at the University of Michigan and at the Company have demonstrated that the use of this system improves the rate of embryo development so that a greater percentage of embryos achieve advanced stages of development.

About Incept BioSystems

Incept BioSystems, Inc., based in Ann Arbor, Michigan, is a privately-held medical device company leveraging its proprietary microscale SMART technology (System of Microfluidics for Assisted Reproductive Technology) platform to improve the in vitro manipulation, performance, and viability of high-value cells for the treatment of patients undergoing in vitro fertilization. The SMART System assisted reproduction device is a cell culture system that can mimic in vivo conditions and is the first microfluidic system that will address the demanding user requirements of fertility professionals while reproducing physiologic conditions ideal for embryo and oocyte culture in the Assisted Reproduction lab. For additional information about Incept BioSystems, visit the Company's website at: http://www.inceptbio.com.

SOURCE Incept BioSystems, Inc.


'/>"/>
SOURCE Incept BioSystems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
2. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
3. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
4. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
5. Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
6. Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
7. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
8. ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)
9. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
10. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
11. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... Oct. 2, 2017  AllianceRx Walgreens Prime, the combined ... Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), ... which included the unveiling of new signage at its ... well as at a few other company-owned facilities across ... to patients, some of whom will begin to see ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... PurhealthRX , a leading Health and Nutrition Company, ... Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market by ... be easily incorporated into liquid products, while reducing costs to end users. , The ...
(Date:10/13/2017)... ... ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to host ... items from across the nation, this holiday-themed event will raise funds and awareness for ... The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 p.m.) ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):